Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02014337 | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | completed | Phase 1 | 37 | Corcept TherapeuticsINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT01949519 | Docetaxel and Lycopene in Metastatic Prostate Cancer | completed | Phase 1 | 24 | Medical University of South CarolinaOTHER | 1 | Jan 11, 2018 | clinicaltrials |
| NCT02514213 |
| Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer |
| completed |
| Phase 1 |
| 62 |
| Inovio PharmaceuticalsINDUSTRY |
| 1 |
| Dec 26, 2017 |
| clinicaltrials |
| NCT00620295 | Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors | completed | Phase 1 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00703638 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01085422 | A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer | completed | Phase 1 | 35 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Nov 21, 2017 | clinicaltrials |
| NCT02705469 | A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 44 | Zenith EpigeneticsINDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02916537 | A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 | completed | Phase 1 | 20 | Cancer Targeted TechnologyINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00331344 | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | completed | Phase 1 / Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02468284 | Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer | completed | Phase 1 | 15 | Ferring PharmaceuticalsINDUSTRY | 1 | Oct 26, 2017 | clinicaltrials |
| NCT02911350 | Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer | completed | Phase 1 | 23 | NYU Langone HealthOTHER | 0 | Oct 2, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT02654938 | Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer | completed | Phase 1 | 32 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01832870 | Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | completed | Phase 1 | 9 | Prostate Oncology Specialists, Inc.OTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00958477 | A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer | completed | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 2, 2017 | clinicaltrials |
| NCT01594918 | Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 25 | Rahul AggarwalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00924313 | Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer | completed | Phase 1 / Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 43 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT03074032 | Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer | completed | Phase 1 | 17 | Avionco LLCINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT02225093 | A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer | completed | Phase 1 | 12 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 27, 2017 | clinicaltrials |
| NCT01911728 | Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | completed | Phase 1 | 14 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00225420 | Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer(NRR) | completed | Phase 1 / Phase 2 | 23 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00670553 | A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer | completed | Phase 1 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | May 17, 2017 | clinicaltrials |
| NCT02022371 | Prostate Cancer Genomic Heterogeneity(PROGENY) | completed | Phase 1 / Phase 2 | 50 | University College London HospitalsOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00574769 | Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT00959335 | Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions | completed | Phase 1 | 36 | SandozINDUSTRY | 0 | Mar 28, 2017 | clinicaltrials |
| NCT00960310 | Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions | completed | Phase 1 | 36 | SandozINDUSTRY | 0 | Mar 28, 2017 | clinicaltrials |
| NCT02198859 | Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer | completed | Phase 1 | 11 | University of Kansas Medical CenterOTHER | 1 | Jan 9, 2017 | clinicaltrials |
| NCT01106352 | A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 70 | BayerINDUSTRY | 2 | Jan 4, 2017 | clinicaltrials |
| NCT01347788 | Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT00946309 | Effects of Sulforaphane on Normal Prostate Tissue(PHASE) | completed | Phase 1 / Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01283373 | A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 84 | Genentech, Inc.INDUSTRY | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00852007 | A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1(MUC1) | completed | Phase 1 / Phase 2 | 20 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 15, 2016 | clinicaltrials |
| NCT00588640 | Study of D-Methadone in Patients With Chronic Pain | completed | Phase 1 / Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01511536 | Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 38 | SanofiINDUSTRY | 3 | Jul 28, 2016 | clinicaltrials |
| NCT00374049 | MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer | completed | Phase 1 | 14 | Olivera FinnOTHER | 1 | Jul 12, 2016 | clinicaltrials |
| NCT00676286 | Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers | completed | Phase 1 | 26 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT02093390 | A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Jun 6, 2016 | clinicaltrials |
| NCT00943956 | Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer | completed | Phase 1 | 30 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT00459186 | The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01378091 | Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer | completed | Phase 1 | 64 | Columbia UniversityOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT01219790 | ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma(GEMO) | completed | Phase 1 | 30 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 19, 2016 | clinicaltrials |
| NCT00345293 | Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer | completed | Phase 1 / Phase 2 | 13 | Rockefeller UniversityOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00811265 | Safety Evaluation of ExAblate MRgFUS for Prostate Cancer | completed | Phase 1 | 10 | InSightecINDUSTRY | 1 | Mar 8, 2016 | clinicaltrials |
| NCT02020291 | Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer | completed | Phase 1 | 31 | WntResearch ABINDUSTRY | 1 | Feb 2, 2016 | clinicaltrials |
| NCT00085566 | Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 61 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Jan 20, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jan 17, 2018source: clinicaltrials